NeuroQuest news

Clinical trial updates, articles and reference material for the AD research community

For the Media

Queries or interviews:
media@neuro-quest.com
phone: 843.696.9382

Publication archives

The Future of Blood-Based Biomarkers for Alzheimer’s Disease

Treatment of Alzheimer’s disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease progression or treatment response, and most are measured in cerebrospinal fluid, which limits their applicability.

read more
Share This